Russian Pharmaceutical Industry Leader
01.04.2022
Pharmasyntez is a nominee for the Platinum Ounce contest
Pharmasyntez is a nominee for the Platinum Ounce contest
Etorelex® claims to receive a special nomination “For National NSAID Segment Development".

On April 14, one of the oldest professional contests of the Russian pharmaceutical market will bring together at the twentieth time the main figures of the pharmaceutical industry, representatives of government authorities and science at the official award ceremony. 

The contest aims to contribute to the formation of a civilized pharmaceutical market and to develop mechanisms to provide people with effective and safe medicines.

The Expert Council of the award consists of the most senior executives of the largest pharmaceutical companies, health agencies, as well as the representatives of competent public organizations and leading medias outlets reporting the events of the pharmaceutical industry.

The award Council selects the winners in the stated nominations and may suggest other special nominations, as well as award colleagues for special services.

One of the special nominations mentioned this year is “For National NSAID Segment Development". Etorelex® manufactured by Pharmasyntez JSC claims to receive this nomination.

Etorelex® (INN: Etoricoxib) is a non-steroidal anti-inflammatory, selective COX-2 inhibitor indicated as a symptomatic therapy of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, pain and inflammation associated with acute gouty arthritis. The drug is also indicated as an immediate therapy of postoperative dental surgery pain.